BREMELANOTIDE PT 141

LIBIDO AND ERECTIONNEUROPEPTIDE

• Molecular Formula: C50H68N14010
• Molecular Weight: 1025.2
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

DESCRIPTION

Bremelanotide(PT-141) was developed from the peptide hormone Melanotan II. In initial testing, Melanotan II induced darkening of skin pigment, but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects. Further testing in animals showed Bremelanotide to induce lordosis (a sexual mating behavior) and subsequently tested for its effect in humans. Although, most of the research has been targeted to women with female sexual dysfunction an it is effective medication in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system. It is estimated that 43% of women (30 million is the US) suffer from sexual dysfunction and 30 million men suffer from ED, with incidence increasing 2-3 fold between ages 40-70. Bremelanotide currently has no contraindications and is 80% effective in men don’t respond to Viagra or Cialis. For women, it causes a 50% increase in sexually satisfying experiences. If FDA approved, it will have the trade name Ayleesi.

PROTOCOL

• Content & Potency: 10mg/ml subcutaneous injection provided in a 2ml vial.
• Suggested dosage: Inject 0.2mL subcutaneously as needed, 30 minutes prior to sexualactivity.The initial dose will establish a time frame for response. Men should start at 0.1ml

CLINICAL RESEARCH

Melanocortins in the treatment of male and female sexual dysfunction. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ.

Abstract: Melanocortinergic agents are currently being investigated for a possible therapeutic role in male and female sexual dysfunction. These investigations were sparked by findings that systemic administration of a synthetic analog of alpha-MSH, MT-II, causes penile erections in a variety of species, including humans. Several other melanocortinergic agents including HP-228, THIQ, and bremelanotide (PT 141) have since been shown to have erectogenic properties thought to be due to binding to melanocortin receptors in the central nervous system, particularly the hypothalamus. Bremelanotide, a nasally administered synthetic peptide, is the only melanocortinergic agent that has been clinically studied in both males and females. Data from Phase II clinical trials of bremelanotide support the use of melanocortin based therapy for erectile dysfunction. Studies using animal models have demonstrated that pre-copulatory behaviors in female rats analogous to sexual arousal are evoked, and preliminary clinical data also suggest a role in promoting sexual desire and arousal in women. Based on bremelanotide clinical experience, administration of a melanocortin agonist is well tolerated and not associated the hypotension observed with phosphodiesterase-5 inhibitors currently used to treat erectile dysfunction. This review discusses investigations of melanocortin agonists for the treatment of sexual dysfunction with emphasis on proposed sites and mechanisms of action in the central nervous system that appear to be involved in melanocortinergic modulation of sexual function.

Here are some reliable sources where you can find information regarding BREMELANOTIDE PT 141:

• Drugs.com – Bremelanotide: Drugs.com is a reputable website that provides information on prescription and over-the-counter medications. Their page on bremelanotide offers an overview of the medication, including its uses, dosage, side effects, and precautions. Link: https://www.drugs.com/mtm/bremelanotide-nasal.html

It’s important to note that while these sources can provide helpful information on bremelanotide, it’s always best to consult with a qualified healthcare provider before taking any medication.

BREMELANOTIDE PT 141 Research

Here are some examples of research studies that have been conducted on the peptide Bremelanotide (PT-141):

1. A study on the effects of PT-141 on sexual dysfunction in premenopausal women: https://www.ncbi.nlm.nih.gov/pubmed/18225963
2. A research article describing the use of PT-141 as a potential treatment for male and female sexual dysfunction: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480574/
3. A study on the effects of PT-141 on food intake and body weight in rats: https://www.ncbi.nlm.nih.gov/pubmed/15184432
4. A review article on the pharmacology and clinical applications of PT-141: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285279/
5. A study on the effects of PT-141 on social behavior in rats: https://www.ncbi.nlm.nih.gov/pubmed/22925630

Please note that this is not an exhaustive list and there may be other studies that have been conducted on PT-141.